Alnylam Pharmaceuticals
ALNY
#573
Rank
S$48.01 B
Marketcap
$372.29
Share price
-0.73%
Change (1 day)
53.17%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -S$0.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$2.09 Billion. In 2023 the company made an earning of -S$0.43 Billion, an increase over its 2022 earnings that were of -S$1.31 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$0.25 Billion-41.96%
2023 -S$0.43 Billion-67.84%
2022 -S$1.31 Billion36.93%
2021 -S$0.96 Billion-8.04%
2020 -S$1.04 Billion-15.66%
2019 -S$1.24 Billion12.23%
2018 -S$1.1 Billion62.91%
2017 -S$0.68 Billion17.78%
2016 -S$0.58 Billion43.44%
2015 -S$0.4 Billion60.69%
2014 -S$0.25 Billion98.2%
2013 -S$0.13 Billion
2011 -S$73.75 Million27.48%
2010 -S$57.86 Million-10.92%
2009 -S$64.95 Million95.77%
2008 -S$33.18 Million
2006 -S$53.15 Million-9.13%
2005 -S$58.49 Million34.74%
2004 -S$43.41 Million36.79%
2003 -S$31.74 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$0.79 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
S$6.68 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.17 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.16 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$55.66 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
S$17.12 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$9.96 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
S$0.56 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel